MDM2 and prostate carcinoma: In summary, we have prepared and characterized an oral nano-delivery system for a novel natural MDM2 inhibitor, GS25, and herein demonstrated its pharmacokinetics, efficacy, and safety in various preclinical models of human prostate cancer.